Future studies will be addressed to verify whether GAS5 and miR-126-3p may be potential early/predictive circulating biomarkers in at high-risk patients (i.e. patients with cirrhosis and/or HBV, HCV chronic hepatitis). Here, GAS5 is linked to chronic hepatitis.